Premium
Feitai , a Chinese herbal medicine, reduces transforming growth factor‐β1 and monocyte chemoattractant protein‐1 expression in bleomycin‐induced lung fibrosis in mice
Author(s) -
Shen Yun,
Zhao HaoLong,
Du Juan,
Li YuTing,
Tan Fang,
Huang ChengGang,
Pei Gang
Publication year - 2005
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2005.04314.x
Subject(s) - bleomycin , pulmonary fibrosis , lung , transforming growth factor , monocyte , medicine , pathogenesis , fibrosis , cytokine , immunology , inflammation , lung fibrosis , cancer research , chemotherapy
Summary 1. Feitai , a Chinese medicine formulation, has been shown to protect against lung fibrosis induced by bleomycin (BLM). In the present study, we investigated the effect of Feitai on transforming growth factor (TGF)‐β1 and monocyte chemoattractant protein‐1 (MCP‐1), which play important roles in the pathogenesis of BLM‐induced lung fibrosis. 2. The results demonstrated that Feitai could significantly attenuate BLM‐induced acute lung inflammation and subsequent lung fibrosis. Meanwhile, the expression of MCP‐1 and TGF‐β 1 mRNA in the lungs increased in the BLM‐treated group compared with the saline‐instilled control group and Feitai treatment significantly decreased cytokine expression in BLM‐treated mice. In addition, Feitai diminished the accumulation of MCP‐1‐ and TGF‐β1‐positive cells in lung tissues at the time of peak mRNA levels. 3. In summary, the results of the present study indicate that treatment with Feitai ameliorates BLM‐induced lung fibrosis, at least in part via the inhibition of MCP‐1 and TGF‐β 1 expression.